Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3155
Predicate | Object |
---|---|
rdf:type | |
rdfs:label |
TRICOR (Tablet)
|
dailymed-instance:dosage |
Patients should be placed
on an appropriate lipid-lowering diet before receiving TRICOR, and
should continue this diet during treatment with TRICOR. TRICOR tablets
can be given without regard to meals. For the treatment of adult patients with primary hypercholesterolemia
or mixed hyperlipidemia, the initial dose of TRICOR is 145 mg per
day. For adult patients
with hypertriglyceridemia, the initial dose is 48 to 145 mg per day.
Dosage should be individualized according to patient response, and
should be adjusted if necessary following repeat lipid determinations
at 4 to 8 week intervals. The maximum dose is 145 mg per day. Treatment with TRICOR should be
initiated at a dose of 48 mg/day in patients having mild to moderately
impaired renal function, and increased only after evaluation of the
effects on renal function and lipid levels at this dose. Lipid levels should be monitored
periodically and consideration should be given to reducing the dosage
of TRICOR if lipid levels fall significantly below the targeted range.
|
dailymed-instance:descripti... |
TRICOR (fenofibrate tablets),
is a lipid regulating agent available as tablets for oral administration.
Each tablet contains 48 mg or 145 mg of fenofibrate. The chemical
name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic
acid, 1-methylethyl ester with the following structural formula: The empirical formula is CHOCl and the molecular weight is 360.83; fenofibrate is insoluble in
water. The melting point is 79-82��C. Fenofibrate is a whitesolid which is stable under ordinary conditions.<br/>Inactive Ingredients: Each tablet contains
hypromellose 2910 (3 cps), docusate sodium, sucrose, sodium lauryl
sulfate, lactose monohydrate, silicified microcrystalline cellulose,
crospovidone, and magnesium stearate. In addition, individual tablets contain:<br/>48 mg tablets: polyvinyl
alcohol, titanium dioxide, talc, soybean lecithin, xanthan gum, D&C
Yellow #10 aluminum lake, FD&C Yellow #6 /sunset yellow FCF aluminum
lake, FD&C Blue #2 /indigo carmine aluminum lake.<br/>145 mg tablets: polyvinyl
alcohol, titanium dioxide, talc, soybean lecithin, xanthan gum.
|
dailymed-instance:clinicalP... |
A variety of clinical studies
have demonstrated that elevated levels of total cholesterol (total-C),
low density lipoprotein cholesterol (LDL-C), and apolipoprotein B
(apo B), an LDL membrane complex, are associated with human atherosclerosis.
Similarly, decreased levels of high density lipoprotein cholesterol
(HDL-C) and its transport complex, apolipoprotein A (apo AI and apo
AII) are associated with the development of atherosclerosis. Epidemiologic
investigations have established that cardiovascular morbidity and
mortality vary directly with the level of total-C, LDL-C, and triglycerides,
and inversely with the level of HDL-C. The independent effect of
raising HDL-C or lowering triglycerides (TG) on the risk of cardiovascular
morbidity and mortality has not been determined. Fenofibric acid, the active metabolite of fenofibrate, produces reductions
in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides
and triglyceride rich lipoprotein (VLDL) in treated patients. In
addition, treatment with fenofibrate results in increases in high
density lipoprotein (HDL) and apoproteins apoAI and apoAII. The effects of fenofibric acid seen
in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures
by the activation of peroxisome proliferator activated receptor��(PPAR��). Through this mechanism, fenofibrate increases lipolysis
and elimination of triglyceride-rich particles from plasma by activating
lipoprotein lipase and reducing production of apoprotein C-III (an
inhibitor of lipoprotein lipase activity). The resulting fall in triglycerides produces an alteration in the
size and composition of LDL from small, dense particles (which are
thought to be atherogenic due to their susceptibility to oxidation),
to large buoyant particles. These larger particles have a greateraffinity for cholesterol receptors and are catabolized rapidly. Activation
of PPAR��also induces an increase in the synthesis of apoproteins
A-I, A-II and HDL-cholesterol. Fenofibrate also reduces serum uric acid levels in hyperuricemic
and normal individuals by increasing the urinary excretion of uric
acid.<br/>Pharmacokinetics/Metabolism: Plasma concentrations
of fenofibric acid after administration of three 48 mg or one 145 mg
tablets are equivalent under fed conditions to one 200 mg capsule.<br/>Absorption: The absolute
bioavailability of fenofibrate cannot be determined as the compound
is virtually insoluble in aqueous media suitable for injection. However,
fenofibrate is well absorbed from the gastrointestinal tract. Following
oral administration in healthy volunteers, approximately 60% of a
single dose of radiolabelled fenofibrate appeared in urine, primarily
as fenofibric acid and its glucuronate conjugate, and 25% was excreted
in the feces. Peak plasma levels of fenofibric acid occur within
6 to 8 hours after administration. Exposure to fenofibric acid in plasma, as measured by Cand AUC, is not significantly different when a single 145 mg dose
of fenofibrate is administered under fasting or nonfasting conditions.<br/>Distribution: Upon multiple
dosing of fenofibrate, fenofibric acid steady state is achieved within
9 days. Plasma concentrations of fenofibric acid at steady state
are approximately double those following a single dose. Serum protein
binding was approximately 99% in normal and hyperlipidemic subjects.<br/>Metabolism: Following
oral administration, fenofibrate is rapidly hydrolyzed by esterases
to the active metabolite, fenofibric acid; no unchanged fenofibrate
is detected in plasma. Fenofibric acid is primarily conjugated with glucuronic acid and
then excreted in urine. A small amount of fenofibric acid is reduced
at the carbonyl moiety to a benzhydrol metabolite which is, in turn,
conjugated with glucuronic acid and excreted in urine. In vivo metabolism data indicate
that neither fenofibrate nor fenofibric acid undergo oxidative metabolism
(e.g., cytochrome P450) to a significant extent.<br/>Excretion: After absorption,
fenofibrate is mainly excreted in the urine in the form of metabolites,
primarily fenofibric acid and fenofibric acid glucuronide. After
administration of radiolabelled fenofibrate, approximately 60% of
the dose appeared in the urine and 25% was excreted in the feces. Fenofibric acid
is eliminated with a half-life of 20 hours, allowing once daily administration
in a clinical setting.<br/>Special Populations:<br/>Geriatrics: In elderly
volunteers 77 - 87 years of age, the oral clearance of fenofibric
acid following a single oral dose of fenofibrate was 1.2 L/h, which
compares to 1.1 L/h in young adults. This indicates that a similar
dosage regimen can be used in the elderly, without increasing accumulation
of the drug or metabolites.<br/>Pediatrics: TRICOR has
not been investigated in adequate and well-controlled trials in pediatric
patients.<br/>Gender: No pharmacokinetic
difference between males and females has been observed for fenofibrate.<br/>Race: The influence
of race on the pharmacokinetics of fenofibrate has not been studied,
however fenofibrate is not metabolized by enzymes known for exhibiting
inter-ethnic variability. Therefore, inter-ethnic pharmacokinetic
differences are very unlikely.<br/>Renal Insufficiency: The pharmacokinetics
of fenofibric acid was examined in patients with mild, moderate, and
severe renal impairment. Patients with severe renal impairment (creatinine
clearance [CrCl]���30 mL/min) showed 2.7-fold increase in exposure
for fenofibric acid and increased accumulation of fenofibric acid
during chronic dosing compared to that of healthy subjects. Patients
with mild to moderate renal impairment (CrCl 30-80 mL/min) had similar
exposure but an increase in the half-life for fenofibric acid compared
to that of healthy subjects. Based on these findings, the use of TRICOR
should be avoided in patients who have severe renalimpairment and
dose reduction is required in patients having mild to moderate renal
impairment.<br/>Hepatic Insufficiency: No pharmacokinetic
studies have been conducted in patients having hepatic insufficiency.<br/>Drug-drug Interactions: In vitro studies using human liver
microsomes indicate that fenofibrate and fenofibric acid are not inhibitors
of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
They are weak inhibitors of CYP2C8, CYP2C19 and CYP2A6, and mild-to-moderate
inhibitors of CYP2C9 at therapeutic concentrations. Potentiation of coumarin-type anticoagulants has been observed with
prolongation of the prothrombin time/INR. Bile acid sequestrants have been shown
to bind other drugs given concurrently. Therefore, fenofibrate should
be taken at least 1 hour before or 4-6 hours after a bile acid binding
resin to avoid impeding its absorption. (See WARNINGS and PRECAUTIONS). Concomitant
administration of fenofibrate (equivalent to TRICOR 145 mg) with pravastatin
(40 mg) once daily for 10 days has been shown to increase the mean
Cand AUC values for pravastatin by 36% (range from
69% decrease to 321% increase) and 28% (range from 54% decrease to
128% increase), respectively, and for 3��-hydroxy-iso-pravastatin
by 55% (range from 32% decrease to 314% increase) and 39% (range from
24% decrease to 261% increase), respectively in 23 healthy adults. Concomitant administration
of a single dose of fenofibrate (equivalent to 145 mg TRICOR) and
a single dose of fluvastatin (40 mg) resulted in a small increase
(approximately 15-16%) in exposure to (+)3R,5S-fluvastatin, the active
enantiomer of fluvastatin. A single dose of either pravastatin or fluvastatin had no clinically
important effect on the pharmacokinetics of fenofibric acid. Concomitant administration
of fenofibrate (equivalent to TRICOR 145 mg) with atorvastatin (20
mg) once daily for 10 days resulted in approximately 17% decrease
(range from 67% decrease to 44% increase) in atorvastatin AUC valuesin 22 healthy males. The atorvastatin Cvalues were
not significantly affected by fenofibrate. The pharmacokinetics of
fenofibric acid were not significantly affected by atorvastatin. Concomitant administration of fenofibrate (equivalent
to TRICOR 145 mg) once daily for 10 days with glimepiride (1 mg tablet)
single dose simultaneously with the last dose of fenofibrate resulted
in a 35% increase in mean AUC of glimepiride in healthy subjects.
Glimepiride Cwas not significantly affected by fenofibrate
co-administration. There was no statistically significant effect of
multiple doses of fenofibrate on glucose nadir or AUC with the baseline
glucose concentration as the covariate after glimepiride administration
in healthy volunteers. However, glucose concentrations at 24 hours
remained statistically significantly lower after pretreatment with
fenofibrate than with glimepiride alone. Glimepiride had no significant
effect on the pharmacokinetics of fenofibric acid. Concomitant administration of fenofibrate (54 mg) and metformin (850
mg) three times a day for 10 days resulted in no significant changes
in the pharmacokinetics of fenofibric acid and metformin when compared
with the two drugs administered alone in healthy subjects. Concomitant administration of fenofibrate (equivalent
to TRICOR 145 mg) once daily for 14 days with rosiglitazone tablet
(rosiglitazone maleate) (8 mg) once daily for 5 days, Day 10 through
Day 14, resulted in no significant changes in the pharmacokinetics
of fenofibric acid and rosiglitazone when compared withthe two drugs
administered alone in healthy subjects. Concomitant
administration of fenofibrate (145 mg TRICOR) with ezetimibe (10 mg)
once daily for 10 days to 18 healthy adults resulted in increases
in total ezetimibe AUC, Cand Cof approximately
43%, 33% and 56%, respectively, and increases in ezetimibe glucuronide
AUC, Cand Cof approximately 49%, 34%
and 62%, respectively. The pharmacokinetics of fenofibric acid were
not significantly affected by ezetimibe and the multiple-dose pharmacokinetics
of free (unconjugated) ezetimibe were not significantly affected by
fenofibrate.<br/>Clinical Trials:<br/>Hypercholesterolemia (Heterozygous Familial and Nonfamilial)
and Mixed Dyslipidemia (Fredrickson Types IIa and IIb): The effects
of fenofibrate at a dose equivalent to 145 mg TRICOR (fenofibrate
tablets) per day were assessed from four randomized, placebo-controlled,
double-blind, parallel-group studies including patients with the following
mean baseline lipid values: total-C 306.9 mg/dL; LDL-C 213.8 mg/dL;
HDL-C 52.3 mg/dL; and triglycerides 191.0 mg/dL. TRICOR therapy
lowered LDL-C, Total-C, and the LDL-C/HDL-C ratio. TRICOR therapy
also lowered triglycerides and raised HDL-C (see Table 1). In a subset
of the subjects, measurements of apo B were conducted. TRICOR treatment
significantly reduced apo B from baseline to endpoint as compared
with placebo (-25.1% vs. 2.4%, p<0.0001, n=213 and
143 respectively).<br/>Hypertriglyceridemia (Fredrickson Type IV and V): The effects
of fenofibrate on serum triglycerides were studied in two randomized,
double-blind, placebo-controlled clinical trialsof 147
hypertriglyceridemic patients (Fredrickson Types IV and V). Patients
were treated for eight weeks under protocols that differed only in
that one entered patients with baseline triglyceride (TG) levels of
500 to 1500 mg/dL, and the other TG levels of 350 to 500 mg/dL. In
patients with hypertriglyceridemia and normal cholesterolemia with
or without hyperchylomicronemia (Type IV/V hyperlipidemia), treatment
with fenofibrate at dosages equivalent to TRICOR 145 mg per day decreased
primarily very low density lipoprotein (VLDL) triglycerides and VLDL
cholesterol. Treatment of patients with Type IV hyperlipoproteinemia
and elevated triglycerides often results in an increase of low density
lipoprotein (LDL) cholesterol (see Table 2). The effect
of TRICOR on cardiovascular morbidity and mortality has not been determined.
|
dailymed-instance:activeIng... | |
dailymed-instance:contraind... |
TRICOR is contraindicated
in patients who exhibit hypersensitivity to fenofibrate. TRICOR is contraindicated in
patients with hepatic or severe renal dysfunction, including primary
biliary cirrhosis, and patients with unexplained persistent liver
function abnormality. TRICOR is contraindicated in patients with preexisting gallbladder
disease (see WARNINGS).
|
dailymed-instance:supply |
TRICOR (fenofibrate
tablets) is available in two strengths: 48 mg yellow tablets, imprinted with���Abbott���A���logo���and Abbo-Code identification
letters "FI", available in bottles of 90 (NDC 0074-6122-90). 145 mg white tablets, imprinted with���Abbott���A���logo���and Abbo-Code identification
letters "FO", available in bottles of 90 (NDC 0074-6123-90).<br/>Storage: Store at 25��C
(77��F); excursions permitted to 15-30��C (59-86��F). [See USP Controlled Room
Temperature]. Keep out of the reach of children. Protect from moisture. Manufactured for Abbott
Laboratories, North Chicago, IL 60064, U.S.A. by Fournier Laboratories Ireland Limited, Anngrove, Carrigtwohill
Co. Cork, Ireland.or Laboratories Fournier SA, Rue de Pres Potets,
21121 Fontaine-les-Dijon, France.
|
dailymed-instance:genericDr... | |
dailymed-instance:activeMoi... | |
dailymed-instance:inactiveI... |
dailymed-ingredient:D&C_Yellow_#10_aluminum_lake,
dailymed-ingredient:FD&C_Blue_#2_/indigo_carmine_aluminum_lake,
dailymed-ingredient:FD&C_Yellow_#6_/sunset_yellow_FCF_aluminum_lake,
dailymed-ingredient:crospovidone,
dailymed-ingredient:docusate_sodium,
dailymed-ingredient:hypromellose_2910_(3cps),
dailymed-ingredient:lactose_monohydrate,
dailymed-ingredient:magnesium_stearate,
dailymed-ingredient:polyvinyl_alcohol,
dailymed-ingredient:silicified_microcrystalline_cellulose,
dailymed-ingredient:sodium_lauryl_sulfate,
dailymed-ingredient:soybean_lecithin,
dailymed-ingredient:sucrose,
dailymed-ingredient:talc,
dailymed-ingredient:titanium_dioxide,
dailymed-ingredient:xanthan_gum
|
dailymed-instance:possibleD... | |
dailymed-instance:overdosag... |
There is no specific treatment
for overdose with TRICOR. General supportive care of the patient
is indicated, including monitoring of vital signs and observation
of clinical status, should an overdose occur. If indicated, elimination
of unabsorbed drug should be achieved by emesis or gastric lavage;
usual precautions should be observed to maintain the airway. Because
fenofibrate is highly bound to plasma proteins, hemodialysis should
not be considered.
|
dailymed-instance:genericMe... |
fenofibrate
|
dailymed-instance:fullName |
TRICOR (Tablet)
|
dailymed-instance:adverseRe... |
Adverse events reported
by 2% or more of patients treated with fenofibrate during the double-blind,
placebo-controlled trials, regardless of causality, are listed in
the table below. Adverse events led to discontinuation of treatment
in 5.0% of patients treated with fenofibrate and in 3.0% treated with
placebo. Increases in liver function tests were the most frequent
events, causing discontinuation of fenofibrate treatment in 1.6% of
patients in double-blind trials. Additional adverse
events reported during post-marketing surveillance or by three or
more patients in placebo-controlled trials or reported in other controlled
or open trials, regardless of causality are listed below.<br/>Body as a Whole: Accidental injury,
allergic reaction, chest pain, cyst, fever, hernia, infection, malaise
and pain (unspecified).<br/>Cardiovascular System: Angina pectoris,
arrhythmia, atrial fibrillation, cardiovascular disorder, coronary
artery disorder, electrocardiogram abnormal, extrasystoles, hypertension,
hypotension, migraine, myocardial infarct, palpitation, peripheral
vascular disorder, phlebitis, tachycardia, varicose vein, vascular
disorder, vasodilatation, venous thromboembolic events (deep vein
thrombosis, pulmonary embolus) and ventricular extrasystoles.<br/>Digestive System: Anorexia, cholecystitis,
cholelithiasis, colitis, diarrhea, duodenal ulcer, dyspepsia, eructation,
esophagitis, flatulence, gastritis, gastroenteritis, gastrointestinal
disorder, increased appetite, jaundice, liver fatty deposit, nausea,
pancreatitis, peptic ulcer, rectal disorder, rectal hemorrhage, tooth
disorder and vomiting.<br/>Endocrine System: Diabetes mellitus.<br/>Hemic and Lymphatic System: Anemia, ecchymosis,
eosinophilia, leukopenia, lymphadenopathy, and thrombocytopenia.<br/>Laboratory Investigations: Alkaline phosphatase
increased, bilirubin increased, blood urea nitrogen increased, serum
creatinine increased, gamma glutamyl transpeptidase increased, lactate
dehydrogenase increased, SGOT and SGPT increased.<br/>Metabolic and Nutritional Disorders: Edema, gout, hyperuricemia,
hypoglycemia, peripheral edema, weight gain, and weight loss.<br/>Musculoskeletal System: Arthralgia, arthritis,
arthrosis, bursitis, joint disorder, leg cramps, myalgia, myasthenia,
myositis, rhabdomyolysis and tenosynovitis.<br/>Nervous System: Anxiety or nervousness,
depression, dizziness, dry mouth, hypertonia, insomnia, libido decreased,
neuralgia, paresthesia, somnolence and vertigo.<br/>Respiratory System: Allergic pulmonary
alveolitis, asthma, bronchitis, cough increased, dyspnea, laryngitis,
pharyngitis, pneumonia and sinusitis.<br/>Skin and Appendages: Acne, alopecia,
contact dermatitis, eczema, fungal dermatitis, herpes simplex, herpes
zoster, maculopapular rash, nail disorder, photosensitivity reaction,
pruritus, rash, sweating, skin disorder, skin ulcer and urticaria.<br/>Special Senses: Abnormal vision,
amblyopia, cataract specified, conjunctivitis, ear pain, eye disorder,
otitis media and refraction disorder.<br/>Urogenital System: Abnormal kidney
function, cystitis, dysuria, gynecomastia, prostatic disorder, unintended
pregnancy, urinary frequency, urolithiasis and vaginal moniliasis.
|
dailymed-instance:warning |
Liver Function: Fenofibrate at doses
equivalent to 96 mg to 145 mg TRICOR per day has been associated with
increases in serum transaminases [AST (SGOT) or ALT (SGPT)]. In a
pooled analysis of 10 placebo-controlled trials, increases to>3
times the upper limit of normal occurred in 5.3% of patients taking
fenofibrate versus 1.1% of patients treated with placebo. When transaminase determinations
were followed either after discontinuation of treatment or during
continued treatment, a return to normal limits was usually observed.
The incidence of increases in transaminases related to fenofibrate
therapy appear to be dose related. In an 8-week dose-ranging study,
the incidence of ALT or AST elevations to at least three times the
upper limit of normal was 13% in patients receiving dosages equivalent
to 96 mg to 145 mg TRICOR per day and was 0% in those receiving dosages
equivalent to 48 mg or less TRICOR per day, or placebo. Hepatocellular,
chronic active and cholestatic hepatitis associated with fenofibrate
therapy have been reported after exposures of weeks to several years.
In extremely rare cases, cirrhosis has been reported in association
with chronic active hepatitis. Regular periodic monitoring of liver function, including serum ALT
(SGPT) should be performed for the duration of therapy with TRICOR,
and therapy discontinued if enzyme levels persist above three times
the normal limit.<br/>Cholelithiasis: Fenofibrate, like
clofibrate and gemfibrozil, may increase cholesterol excretion into
the bile, leading to cholelithiasis. If cholelithiasis is suspected,
gallbladder studies are indicated. TRICOR therapy should be discontinued
if gallstones are found.<br/>Concomitant Oral Anticoagulants: Caution should be
exercised when anticoagulants are given in conjunction with TRICOR
because of the potentiation of coumarin-type anticoagulants in prolonging
the prothrombin time/INR. The dosage of the anticoagulant should
be reduced to maintain the prothrombin time/INR at the desired level
to prevent bleeding complications. Frequent prothrombin time/INR
determinations are advisable until it has been definitely determined
that the prothrombin time/INR has stabilized.<br/>Concomitant HMG-CoA Reductase Inhibitors: The combined use
of TRICOR and HMG-CoA reductase inhibitors should be avoided unless
the benefit of further alterations in lipid levels is likely to outweigh
the increased risk of this drug combination. Concomitant administration of fenofibrate (equivalent to TRICOR 145
mg) and pravastatin (40 mg) once daily for 10 days increased the mean
Cand AUC values for pravastatin by 36% (range from
69% decrease to 321% increase) and 28% (range from 54% decrease to
128% increase), respectively, and for 3��-hydroxy-iso-pravastatin
by 55% (range from 32% decrease to 314% increase) and 39% (range from
24% decrease to 261% increase), respectively. (See also CLINICAL PHARMACOLOGY, Drug-drug Interactions). The combined
use of fibric acid derivatives and HMG-CoA reductase inhibitors has
been associated, in the absence of a marked pharmacokinetic interaction,
in numerous case reports, with rhabdomyolysis, markedly elevated creatine
kinase (CK) levels and myoglobinuria, leading in a high proportion
of cases to acute renal failure. The use of fibrates alone, including TRICOR, may occasionally be
associated with myositis, myopathy, or rhabdomyolysis. Patients receiving
TRICOR and complaining of muscle pain, tenderness, or weakness should
have prompt medical evaluation for myopathy, including serum creatine
kinase level determination. If myopathy/myositis is suspected or
diagnosed, TRICOR therapy should be stopped.<br/>Mortality: The effect of TRICOR
on coronary heart disease morbidity and mortality and non-cardiovascular
mortality has not been established.<br/>Other Considerations: The Fenofibrate
Intervention and Event Lowering in Diabetes (FIELD) study was a 5-year
randomized, placebo-controlled study of 9795 patients with type 2
diabetes mellitus treated with fenofibrate. Fenofibrate demonstrated
a non-significant 11% relative reduction in the primary outcome of
coronary heart disease events (hazard ratio [HR] 0.89, 95% CI 0.75-1.05,
p=0.16) and a significant 11% reduction in the secondary outcome of
total cardiovascular disease events (HR 0.89 [0.80-0.99], p=0.04).
There was a non-significant 11% (HR 1.11 [0.95, 1.29], p=0.18) and
19% (HR 1.19 [0.90, 1.57], p=0.22) increase in total and coronary
heart disease mortality, respectively, with fenofibrate as compared
to placebo. In
the Coronary Drug Project, a large study of post myocardial infarction
of patients treated for 5 years with clofibrate, there was no difference
in mortality seen between the clofibrate group and the placebo group.
There was however, a difference in the rate of cholelithiasis and
cholecystitis requiring surgery between the two groups (3.0% vs. 1.8%). Because of chemical, pharmacological,
and clinical similarities between TRICOR (fenofibrate tablets), Atromid-S
(clofibrate), and Lopid (gemfibrozil), the adverse findings in 4 large
randomized, placebo-controlled clinical studies with these other fibrate
drugs may also apply to TRICOR. In a study conducted by the World Health Organization (WHO), 5000
subjects without known coronary artery disease were treated with placebo
or clofibrate for 5 years and followed for an additional one year.
There was a statistically significant, higher age���adjusted
all-cause mortality in the clofibrate group compared with the placebo
group (5.70% vs. 3.96%, p =<0.01). Excess mortality was due
to a 33% increase in non-cardiovascular causes, including malignancy,
post-cholecystectomy complications, and pancreatitis. This appeared
to confirm the higher risk of gallbladder disease seen in clofibrate-treated
patients studied in the Coronary Drug Project. The Helsinki Heart Study was a large (n=4081) study of middle-aged
men without a history of coronary artery disease. Subjects received
either placebo or gemfibrozil for 5 years, with a 3.5 year open
extension afterward. Total mortality was numerically higher in the
gemfibrozil randomization group but did not achieve statistical significance
(p = 0.19, 95% confidence interval for relative risk G:P =
.91-1.64). Although cancer deaths trended higher in the gemfibrozil
group (p = 0.11), cancers (excluding basal cell carcinoma)
were diagnosed with equal frequency in both study groups. Due to
the limited size of the study, the relative risk of death from any
cause was not shown to be different than that seen in the 9 year follow-up
data from World Health Organization study (RR=1.29). Similarly, the
numerical excess of gallbladder surgeries in the gemfibrozil group
did not differ statistically from that observed in the WHO study. A secondary prevention
component of the Helsinki Heart Study enrolled middle-aged men excluded
from the primary prevention study because of known or suspected coronary
heart disease. Subjects received gemfibrozil or placebo for 5 years.
Although cardiac deaths trended higher in the gemfibrozil group,
this was not statistically significant (hazard ratio 2.2, 95% confidence
interval: 0.94-5.05). The rate of gallbladder surgery was not statistically
significant between study groups, but did trend higher in the gemfibrozil
group, (1.9% vs. 0.3%, p = 0.07). There was a statistically
significant difference in the number of appendectomies in the gemfibrozil
group (6/311 vs. 0/317, p = 0.029).
|
dailymed-instance:indicatio... |
Treatment of Hypercholesterolemia: TRICOR is indicated
as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides
and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia
or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering
agents should be used in addition to a diet restricted in saturated
fat and cholesterol when response to diet and non-pharmacological
interventions alone has been inadequate (see National Cholesterol
Education Program [NCEP] Treatment Guidelines, below).<br/>Treatment of Hypertriglyceridemia: TRICOR is also indicated
as adjunctive therapy to diet for treatment of adult patients with
hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia).
Improving glycemic control in diabetic patients showing fasting chylomicronemia
will usually reduce fasting triglycerides and eliminate chylomicronemia
thereby obviating the need for pharmacologic intervention. Markedly elevated levels
of serum triglycerides (e.g.>2,000 mg/dL) may increase the risk
of developing pancreatitis. The effect of TRICOR therapy on reducing
this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia,
who have elevations of chylomicrons and plasma triglycerides, but
who have normal levels of very low density lipoprotein (VLDL). Inspection
of plasma refrigerated for 14 hours is helpful in distinguishing Types
I, IV and V hyperlipoproteinemia. The initial treatment for dyslipidemia is dietary therapy specific
for the type of lipoprotein abnormality. Excess body weight and excess
alcoholic intake may be important factors in hypertriglyceridemia
and should be addressed prior to any drug therapy. Physical exercise
can be an important ancillary measure. Diseases contributory to hyperlipidemia,
such as hypothyroidism or diabetes mellitus should be looked for and
adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers,
are sometimes associated with massive rises in plasma triglycerides,
especially in subjects with familial hypertriglyceridemia. In such
cases, discontinuation of the specific etiologic agent may obviate
the need for specific drug therapy of hypertriglyceridemia. The use of drugs should
be considered only when reasonable attempts have been made to obtain
satisfactory results with non-drug methods. If the decision is made
to use drugs, the patient should be instructed that this does not
reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS). After the LDL-C
goal has been achieved, if the TG is still���200 mg/dL, non
HDL-C (total-C minus HDL-C) becomes a secondary target of therapy.
Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each
risk category.
|
dailymed-instance:represent... | |
dailymed-instance:routeOfAd... | |
dailymed-instance:name |
TRICOR
|